tumor targeting used consists of radioactive nuclides immune response agents and chelated the L- enantiomeric oligonucleotide complex

摘要

(57) A non-radioactive targeting immunoreagents, immunoreactive group, non-self associating L- enantiomeric oligonucleotide sequence of one or more, and [Abstract] The present invention, those containing the linking group of 1 or more, can be, as well as a radioactive targeting immune reagents, is complementary in sequence to a fragment of one or more of the non-self-association of L- enantiomeric oligonucleotide sequences to hybridize with the fragment L- enantiomeric oligonucleotide sequence , which is directed chelating agents, one or more linking groups of 1 or more, and containing one radionuclide or more. The present invention, I is directed to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and the immunity one or more reagents. The invention is further directed to a method for the imaging and treatment of disease sites in a patient.